If you are taking Prozac to help stabilize your mood, the addition of semaglutide may make it harder to notice changes in your mental health
Boehringer Ingelheim and Zealand Pharma commenced Phase 3 SYNCHRONIZE trials for survodutide, a dual GLP-1/glucagon agonist, targeting both obesity and metabolic dysfunction-associated steatohepatitis
385,387 PF1801 displays its anti-inflammatory effects by lowering levels of inflammatory mediators such as TNF, IL-6, and HMGB1, and enhances the cells antioxidant capability by upregulating molecules like Nfe2l2, Hmox1, Gclm, and Nqo1, which further improves cellular defense against oxidative stress and protects them from further damage
PMC6271067 Seiwerth, S., et al
Dual agonists typically target GLP-1R, GIP (glucose-dependent insulinotropic polypeptide) or IGF (insulin-like growth factor) receptors, while triple agonists target GLP-1R, GIPR, and the glucagon receptor (GCGR)